Compare Ishares Msci Spain ETF (EWP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Neurocrine Biosciences Inc — how do they compare? Ishares Msci Spain ETF trades at $59.18, while Neurocrine Biosciences Inc trades at $171.8 (market cap $17.30B). Which is the better fit depends on your goals.
| EWP | NBIX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $60.28 | $180.55 |
52-Week Low | $43.90 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $59.26, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend, supported by strong moving average alignment, while oscillators remain neutral. The stock exhibits tight support at $59 and resistance at $60. A dividend of $0.92 per share is scheduled for payment on June 18, 2026.
The outlook for EWP is cautiously optimistic due to bullish technicals and upcoming dividend returns. Key risks include European economic sensitivity to energy price volatility and potential interest rate impacts. Investors should monitor ECB policy decisions and regional economic performance for directional cues.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
